<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Despite <z:hpo ids='HP_0000001'>all</z:hpo> efforts in extending the resectability rates of colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, thus improving the prognosis of the patients, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence occurs in many patients </plain></SENT>
<SENT sid="1" pm="."><plain>Occult dissemination of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells might reflect a <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> that is not eliminated by primary surgery </plain></SENT>
<SENT sid="2" pm="."><plain>Because the prognostic effect of disseminated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells (<z:chebi fb="17" ids="53093">DTC</z:chebi>) is still uncertain in this clinical setting, we analyzed these cells in the peripheral blood and bone marrow of patients undergoing hepatic resection of colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: In 108 patients with colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, the presence of <z:chebi fb="17" ids="53093">DTC</z:chebi> in the peripheral blood and bone marrow was detected with CK20 RT-PCR </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical data were prospectively collected, and multiple variables were analyzed regarding their influence on overall survival </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="17" ids="53093">DTC</z:chebi> in the peripheral blood were detected in 40% of the patients </plain></SENT>
<SENT sid="6" pm="."><plain>In 25% of the patients, <z:chebi fb="17" ids="53093">DTC</z:chebi> were detected in the bone marrow </plain></SENT>
<SENT sid="7" pm="."><plain>The median follow-up was 34 months </plain></SENT>
<SENT sid="8" pm="."><plain>Fifty-nine of 108 patients died from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> relapse </plain></SENT>
<SENT sid="9" pm="."><plain>Multivariate analysis determined detection of <z:chebi fb="17" ids="53093">DTC</z:chebi> in the bone marrow to be an independent prognostic factors for overall survival (P = 0.038) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: This large series of patients with hepatic resection of colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> demonstrated that detection of CK20-positive <z:chebi fb="17" ids="53093">DTC</z:chebi> via RT-PCR in the bone marrow compartment negatively influences overall survival </plain></SENT>
<SENT sid="11" pm="."><plain>The evidence of <z:chebi fb="17" ids="53093">DTC</z:chebi> in the bone marrow might serve as an additional individual marker to select patients for adjuvant treatment after <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> resection </plain></SENT>
</text></document>